ARTICLE | Emerging Company Profile
Incyclix Bio: overcoming drug resistance in breast and ovarian cancer
G1 licensee Incyclix is developing molecules selective for a target G1 was trying to avoid
April 2, 2022 12:05 AM UTC
Incyclix is parlaying data from parent company G1 Therapeutics, which is developing inhibitors selective for CDK4/6 over CDK2, to do the reverse. The biotech is betting its CDK2-selective compounds can overcome drug resistance mechanisms in breast and ovarian cancer.
On Thursday, Incyclix Bio LLC announced a $30 million series B round led by new investor Boxer Capital, with participation by new investor RA Capital Management and existing investor Eshelman Ventures. ...